Business Wire

HPCAIAC

8.4.2020 14:32:09 CEST | Business Wire | Press release

Share
HPC-AI Advisory Council and National Supercomputing Centre Singapore Expand 3rd APAC HPC-AI Competition to Address COVID-19

The HPC-AI Advisory Council (HPCAIAC) and the National Supercomputing Centre (NSCC) Singapore announced today that they have joined the global fight against COVID-19 by expanding the 2020 APAC HPC-AI competition to address education and applied learning towards accelerating bioscience research and discovery.

As part of the updated competition, student teams are now tasked to research, find and choose an HPC or AI application that can potentially be used as part of the global fight against COVID-19. Teams must demonstrate testing and benchmarking of the application, as well as explain how this application can best be accelerated. In addition, teams will also be required to focus on tuning and accelerating NAMD, a molecular dynamics code designed for high-performance simulation of large biomolecular systems. The NAMD application is being used at various supercomputing sites to run massive simulations of COVID-19 to aid researchers design new drugs and vaccines to combat the virus.

The APAC HPC-AI competition promotes the latest HPC and AI technologies to the universities and research centers and trains the students with the latest HPC and AI technologies to help bridge the gap between universities/research institutes and industries. The competition also trains the undergraduate and graduate students to practice on the newest HPC and AI platforms, and provides the key ingredients and industry tools to optimize the production applications. Open for registration until May 17, the 3rd Annual 2020 APAC HPC-AI competition expects to host multiple teams from across the APAC region.

“While not ignoring commercial and scientific applications, it has become importantly clear that we must put further emphasis on tuning and optimizing applications in the medical and bioscience field. By expanding the competition’s charter to address applications specifically used for groundbreaking COVID-19 simulations, the HPC-AI Advisory Council and NSCC are taking the action to educate and train the next generation of HPC scientists and programmers that may aid the world in viral outbreaks or pandemics in the future,” said Gilad Shainer, Chairman of the HPC-AI Advisory Council.

"Computer models of viruses and viral protein structures, especially for high resolution analysis, is very computationally intensive. Molecular docking experiments in silico, to screen for potentially effective drugs that block viral functions, and molecular-modeling applications, such as GROMACS and NAMD, must be optimized and benchmarked for simulations to run as efficiently as possible. By training our young aspiring programmers using real-world scenarios such as COVID-19, we can better prepare them to provide solutions to future global issues from pandemics to climate change. More than that, we hope that this will give our youth a better appreciation for the significant role that HPC and AI can play, and how they can use the skills learned in this competition to contribute more meaningfully to society," said Professor Tan Tin Wee, Chief Executive, National Supercomputing Centre (NSCC) Singapore.

Co-organized by the HPC-AI Advisory Council and NSCC, the competition is sponsored by Mellanox, NVIDIA, AMD and WekaIO with additional support from the Singapore Advanced Research and Education Network (SingAREN).

For more information on the 3rd APAC HPC-AI competition and to register teams, please visit the HPC-AI Advisory Council website at http://hpcadvisorycouncil.com/events/2020/APAC-AI-HPC/

About HPC-AI Advisory Council

Founded in 2008, The HPC-AI Advisory Council (HPCAIAC) is a for community benefit organization with over 400 members committed to bridge the gap between high-performance computing and artificial intelligence use and its potential, bringing the beneficial capabilities of HPC and AI to new users for better research, education, innovation and product manufacturing, and brings users the expertise needed to operate HPC and AI systems, provide application designers with the tools needed to enable parallel computing, and to strengthen the qualification and integration of HPC and AI system products. For more information, please visit: www.hpcadvisorycouncil.com .

About National Supercomputing Centre Singapore

The National Supercomputing Centre (NSCC) Singapore was established in 2015 and manages Singapore’s first national petascale facility with available high performance computing (HPC) resources. As a National Research Infrastructure we support the HPC research needs of the public and private sectors, including research institutes, institutes of higher learning, government agencies and companies. With the support of its stakeholders, including Agency for Science Technology and Research (A*STAR), Nanyang Technological University (NTU), National University of Singapore (NUS), Singapore University of Technology and Design (SUTD), National Environment Agency (NEA) and Technology Centre for Offshore and Marine, Singapore (TCOMS), and funded by the National Research Foundation (NRF), NSCC catalyses national research and development initiatives, attracts industrial research collaborations and enhances Singapore’s research capabilities. For more information, please visit https://www.nscc.sg/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye